Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

Endocrine-Related Cancer - Tập 22 Số 1 - Trang 1-9 - 2015
Mauro Cives1, Pamela L. Kunz2, Brian Morse1, Domenico Coppola1, Michael J. Schell1, Tiffany Campos1, Phuong Nguyen1, Prachi Nandoskar2, Vilay H. Khandelwal2, Jonathan Strosberg1
1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
2Department of Medicine, Stanford University School of Medicine, Stanford, California USA

Tóm tắt

Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotidein vitro. This open-label, phase II study assessed the clinical activity of pasireotide in treatment-naïve patients with metastatic grade 1 or 2 NETs. Patients with metastatic pancreatic and extra-pancreatic NETs were treated with pasireotide LAR (60 mg every 4 weeks). Previous systemic therapy, including octreotide and lanreotide, was not permitted. Tumor assessments were performed every 3 months using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), overall radiographic response rate (ORR), and safety. Twenty-nine patients were treated with pasireotide LAR (60 mg every 4 weeks) and 28 were evaluable for response. The median PFS was 11 months. The most favorable effect was observed in patients with low hepatic tumor burden, normal baseline chromogranin A, and high tumoral SSTR5expression. Median OS has not been reached; the 30-month OS rate was 70%. The best radiographic response was partial response in one patient (4%), stable disease in 17 patients (60%), and progressive disease in ten patients (36%). Although grade 3/4 toxicities were rare, pasireotide LAR treatment was associated with a 79% rate of hyperglycemia including 14% grade 3 hyperglycemia. Although pasireotide appears to be an effective antiproliferative agent in the treatment of advanced NETs, the high incidence of hyperglycemia raises concerns regarding its suitability as a first-line systemic agent in unselected patients. SSTR5expression is a potentially predictive biomarker for response.

Từ khóa


Tài liệu tham khảo

2014, New England Journal of Medicine, 371, 224, 10.1056/NEJMoa1316158

Colao, 2012, New England Journal of Medicine, 366, 914, 10.1056/NEJMoa1105743

2014, Journal of Clinical Endocrinology & Metabolism, 99, 791, 10.1210/jc.2013-2480

2012, European Journal of Endocrinology, 166, 821, 10.1530/EJE-11-0773

2003, Journal of Clinical Oncology, 21, 2689, 10.1200/JCO.2003.12.142

2014, Current medicinal chemistry, 21, 1017, 10.2174/09298673113209990237

2009, Journal of Clinical Endocrinology & Metabolism, 94, 428, 10.1210/jc.2008-1712

2012, JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10, 724, 10.6004/jnccn.2012.0075

Kvols, 1986, New England Journal of Medicine, 315, 663, 10.1056/NEJM198609113151102

2012, Endocrine-Related Cancer, 19, 657, 10.1530/ERC-11-0367

Nasir, 2006, Cancer control : journal of the Moffitt Cancer Center, 13, 52, 10.1177/107327480601300108

ONO, 2007, Anticancer Research, 27, 2231

2009, Journal of Clinical Oncology, 27, 4656, 10.1200/JCO.2009.22.8510

Schmid, 2008, Molecular and cellular endocrinology, 286, 69, 10.1016/j.mce.2007.09.006

2004, Neuroendocrinology, 80, S47, 10.1159/000080741

2014, American journal of therapeutics, 21, 164, 10.1097/MJT.0b013e31824c3eb4

2012, The Oncologist, 17, 747, 10.1634/theoncologist.2011-0458

2013, Neuroendocrinology, 97, 183, 10.1159/000341810

Therasse, 2000, JNCI Journal of the National Cancer Institute, 92, 205, 10.1093/jnci/92.3.205

Villaume, 2010, Neuroendocrinology, 91, 268, 10.1159/000289569

2013, Journal of Clinical Oncology, 31, 15s, 10.1200/JCO.2012.43.3730

2013, Cancer chemotherapy and pharmacology, 72, 387, 10.1007/s00280-013-2202-1

Yao, 2011, New England Journal of Medicine, 364, 514, 10.1056/NEJMoa1009290

Thông tin
Thông tin xuất bản

Endocrine-Related Cancer

Tập 22 Số 1

1-9

Thông tin tác giả